Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study
复制标题
DOI：
10.1016/s1470-2045(19)30693-x
复制
发表时间：
2020-01-01
期刊：
影响因子：
51.1
通讯作者：
Trippett, Tanya
中科院分区：
文献类型：
--
作者：
Geoerger, Birgit;Zwaan, C. Michel;Trippett, Tanya
Atezolizumab是一种PD-L1抑制剂，可增强抗癌t细胞活性。我们的目的是评估atezolizumab在患有已知或预期PD-L1表达的难治性或复发性实体瘤的儿童和年轻人中的安全性、药代动力学和活性。方法：iMATRIX是一项多中心、开放标签、1-2期临床试验
Background Atezolizumab is an inhibitor of PD-L1, which can lead to enhanced anticancer T-cell activity. We aimed to evaluate the safety, pharmacokinetics, and activity of atezolizumab in children and young adults with refractory or relapsed solid tumours, with known or expected PD-L1 expression.Methods iMATRIX was a multicentre, open-label, phase 1-2 trial of patients (aged